Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies

Trabectedin and its potential in the treatment of soft tissue sarcoma

(2016) J Fayette   Therapeutics and Clinical Risk Management

Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer

(2010) Bradley J. Monk et al.   JOURNAL OF CLINICAL ONCOLOGY

In vitro studies on the metabolism of trabectedin (YONDELIS®) in monkey and man, including human CYP reaction phenotyping

(2009) Marc Vermeir et al.   BIOCHEMICAL PHARMACOLOGY

Trabectedin for the management of soft-tissue sarcoma

(2009) Laurence Boudou et al.   Expert Review of Anticancer Therapy

Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules

(2009) George D. Demetri et al.   JOURNAL OF CLINICAL ONCOLOGY

Period Correction of the QTc of Moxifloxacin With Multiple Predose Baseline ECGs Is the Least Variable of 4 Methods Tested

(2009) Xiaoping Zhang et al.   JOURNAL OF CLINICAL PHARMACOLOGY

A Thorough QTc Study to Assess the Effect of Sitagliptin, a DPP4 Inhibitor, on Ventricular Repolarization in Healthy Subjects

(2009) Daniel M. Bloomfield et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Electrocardiographic QTc Changes Due to Moxifloxacin Infusion

(2009) Marek Malik et al.   JOURNAL OF CLINICAL PHARMACOLOGY

The Effect of Moxifloxacin on QTc and Implications for the Design of Thorough QT Studies

(2008) DM Bloomfield et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Raltegravir Thorough QT/QTc Study: A Single Supratherapeutic Dose of Raltegravir Does Not Prolong the QTcF Interval

(2008) M. Iwamoto et al.   JOURNAL OF CLINICAL PHARMACOLOGY